dc.contributor.author |
Asiedu, Bernice
|
|
dc.contributor.author |
Lembede, Busisani Wiseman
|
|
dc.contributor.author |
Gomes, Monica N.
|
|
dc.contributor.author |
Kasonga, Abe E.
|
|
dc.contributor.author |
Nkomozepi, Pilani
|
|
dc.contributor.author |
Nyakudya, Trevor Tapiwa
|
|
dc.contributor.author |
Chivandi, Eliton
|
|
dc.date.accessioned |
2023-03-30T09:36:11Z |
|
dc.date.available |
2023-03-30T09:36:11Z |
|
dc.date.issued |
2023-01 |
|
dc.description.abstract |
Alcohol intake at different developmental stages can lead to the development of alcohol-induced fatty liver disease (AFLD). Zingerone (ZO) possess hepato-protective properties; thus, when administered neonatally, it could render protection against AFLD. This study aimed to evaluate the potential long-term protective effect of ZO against the development of AFLD. One hundred and twenty-three 10-day-old Sprague–Dawley rat pups (60 males; 63 females) were randomly assigned to four groups and orally administered the following treatment regimens daily during the pre-weaning period from postnatal day (PND) 12–21: group 1—nutritive milk (NM), group 2—NM +1 g/kg ethanol (Eth), group 3—NM + 40 mg/kg ZO, group 4—NM + Eth +ZO. From PND 46–100, each group from the neonatal stage was divided into two; subgroup I had tap water and subgroup II had ethanol solution as drinking fluid, respectively, for eight weeks. Mean daily ethanol intake, which ranged from 10 to 14.5 g/kg body mass/day, resulted in significant CYP2E1 elevation (p < 0.05). Both late single hit and double hit with alcohol increased liver fat content, caused hepatic macrosteatosis, dysregulated mRNA expression of SREBP1c and PPAR-α in male and female rats (p < 0.05). However, neonatal orally administered ZO protected against liver lipid accretion and SREBP1c upregulation in male rats only and attenuated the alcohol-induced hepatic PPAR-α downregulation and macrosteatosis in both sexes. This data suggests that neonatal orally administered zingerone can be a potential prophylactic agent against the development of AFLD. |
en_US |
dc.description.department |
Physiology |
en_US |
dc.description.librarian |
hj2023 |
en_US |
dc.description.sponsorship |
The National Research Foundation (NRF) Thuthuka Fund and the Medical Faculty Research Endowment Fund, Faculty of Health Sciences Research Committee and School of Physiology of the University of Witwatersrand. |
en_US |
dc.description.uri |
https://www.mdpi.com/journal/metabolites |
en_US |
dc.identifier.citation |
Asiedu, B.; Lembede, B.W.;
Gomes, M.; Kasonga, A.; Nkomozepi,
P.; Nyakudya, T.T.; Chivandi, E.
Neonatal Orally Administered
Zingerone Attenuates
Alcohol-Induced Fatty Liver Disease
in Experimental Rat Models.
Metabolites 2023, 13, 167.
https://doi.org/10.3390/metabo13020167. |
en_US |
dc.identifier.issn |
2218-1989 (online) |
|
dc.identifier.other |
10.3390/metabo13020167 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/90272 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
MDPI |
en_US |
dc.rights |
© 2023 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/). |
en_US |
dc.subject |
Alcohol-induced fatty liver disease (AFLD) |
en_US |
dc.subject |
Zingerone |
en_US |
dc.subject |
Macrosteatosis |
en_US |
dc.subject |
Sterol regulatory element binding protein 1c (SREBP1c) |
en_US |
dc.subject |
Peroxisome proliferator activator receptor-alpha (PPAR-α) |
en_US |
dc.title |
Neonatal orally administered zingerone attenuates alcohol-induced fatty liver disease in experimental rat models |
en_US |
dc.type |
Article |
en_US |